NCT05689762 Promotion of Healthy Lifestyle Habits in Primary Care Settings
| NCT ID | NCT05689762 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Örebro University, Sweden |
| Condition | Healthy Lifestyle |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-06-22 |
| Primary Completion | 2028-01-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-06-22 with a primary completion date of 2028-01-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Intervention aiming to promote healthy dietary and physical activity behaviors in adults with different socioeconomic status primary care settings
Eligibility Criteria
Inclusion Criteria: * age, high metabolic risk- poor lifestyle habits (diet and physical activity) Exclusion Criteria: * overt disease
Contact & Investigator
Fawzi Kadi, professor
PRINCIPAL INVESTIGATOR
Örebro University, Sweden
Frequently Asked Questions
Who can join the NCT05689762 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 70 Years, studying Healthy Lifestyle. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05689762 currently recruiting?
Yes, NCT05689762 is actively recruiting participants. Contact the research team at fawzi.kadi@oru.se for enrollment information.
Where is the NCT05689762 trial being conducted?
This trial is being conducted at Örebro, Sweden.
Who is sponsoring the NCT05689762 clinical trial?
NCT05689762 is sponsored by Örebro University, Sweden. The principal investigator is Fawzi Kadi, professor at Örebro University, Sweden. The trial plans to enroll 100 participants.